Abstract
Objective: This longitudinal systematic gene expression study focuses on multiple sclerosis (MS) and the effects of medication by recombinant Interferon-beta-1a (IFNb1a). It is the aim to infer accessory regulatory pathways of the applied drug and to detect surrogate markers for therapeutic intervention in human PBMCs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.